المؤلفون: Chanchlani, N, Lin, S, Bewshea, C, Hamilton, B, Thomas, A, Smith, R, Roberts, C, Bishara, M, Nice, R, Lees, CW, Sebastian, S, Irving, PM, Russell, RK, McDonald, TJ, Goodhand, JR, Ahmad, T, Kennedy, NA, Patel, V, Mazhar, Z, Saich, R, Colleypriest, B, Tham, TC, Iqbal, T, Kaushik, V, Murugesan, S, Singh, S, Weaver, S, Preston, C, Butt, A, Smith, M, Basude, D, Beale, A, Langlands, S, Direkze, N, Parkes, M, Torrente, F, De La Revella Negro, J, MacDonald, CE, Evans, SM, Gunasekera, AVJ, Thakur, A, Elphick, D, Shenoy, A, Nwokolo, CU, Dhar, A, Cole, AT, Agrawal, A, Bridger, S, Doherty, J, Cooper, SC, de Silva, S, Mowat, C, Mayhead, P, Lees, C, Jones, G, Hart, JW, Al-Nuaimi, Y, Richards, E, Haigh, R, Greenish, H, Heath, H, Gaya, DR, Gervais, L, Dunckley, P, Mahmood, T, Banim, PJR, Sonwalkar, S, Ghosh, D, Phillips, RH, Azaz, A, Shenderey, R, Armstrong, L, Bell, C, Hariraj, R, Matthews, H, Jafferbhoy, H, Selinger, CP, Zamvar, V, De Caestecker, JS, Willmott, A, Miller, R, Babu, PS, Tzivinikos, C, Bloom, SL, Chung-Faye, G, Croft, NM, Fell, JME, Harbord, M, Hart, A, Hope, B, Lindsay, JO, Mawdsley, JE, McNair, A, Monahan, KJ, Murray, CD, Orchard, T, Paul, T, Pollok, R, Shah, N, Bouri, S, Johnson, MW, Modi, A, Kabiru, KD, Baburajan, BK, Bhaduri, B, Fagbemi, AA, Levison, S, Limdi, JK, Watts, G, Foley, S, Ramadas, A, MacFaul, G, Mansfield, J, Grellier, L, Morris, M-A, Tremelling, M, Hawkey, C, Kirkham, S, Charlton, CPJ, Rodrigues, A, Simmons, A, Lewis, SJ, Snook, J, Tighe, M, Goggin, PM, De Silva, AN, Lal, S, Smith, MS, Panter, S, Cummings, JRF, Dharmisari, S, Carter, M, Watts, D, Mahmood, Z, McLain, B, Sen, S, Pigott, AJ, Hobday, D, Wesley, E, Johnston, R, Edwards, C, Beckly, J, Vani, D, Ramakrishnan, S, Chaudhary, R, Trudgill, NJ, Cooney, R, Bell, A, Prasad, N, Gordon, JN, Brookes, MJ, Li, A, Gore, S

الوصف: This is the final version. Available from Elsevier via the DOI in this record. ; Background We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. Methods Personalised Anti-TNF therapy in Crohn’s disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn’s disease aged 6 years and older. At the end of the first year, sites were invited to enrol participants still receiving study drug into the 2-year PANTS-extension study. We estimated rates of remission across the whole cohort at the end of years 1, 2, and 3 of the study using a modified survival technique with permutation testing. Multivariable regression and survival analyses were used to identify factors associated with loss of response in patients who had initially responded to anti-TNF therapy and with immunogenicity. Loss of response was defined in patients who initially responded to anti-TNF therapy at the end of induction and who subsequently developed symptomatic activity that warranted an escalation of steroid, immunomodulatory, or anti-TNF therapy, resectional surgery, or exit from study due to treatment failure. This study was registered with ClinicalTrials.gov, NCT03088449, and is now complete. Findings Between March 19, 2014, and Sept 21, 2017, 389 (41%) of 955 patients treated with infliximab and 209 (32%) of 655 treated with adalimumab in the PANTS study entered the PANTS-extension study (median age 32·5 years [IQR 22·1–46·8], 307 [51%] of 598 were female, and 291 [49%] were male). The estimated proportion of patients in remission at the end of years 1, 2, and 3 were, for infliximab 40·2% (95% CI 36·7–43·7), 34·4% (29·9–39·0), and 34·7% (29·8–39·5), and for adalimumab 35·9% (95% CI 31·2–40·5), 32·9% (26·8–39·2), and 28·9% (21·9–36·3), ...

العلاقة: Data sharing Individual participant de-identified raw data and a data dictionary defining each field in the set that underlie the results reported in this Article will be available immediately after publication for a period of 5 years. The data will be made available to investigators whose proposed use of the data has been approved by an independent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to Tariq Ahmad (tariq.ahmad1@nhs.net). To gain access data, requestors will need to sign a data access agreement.; The Lancet Gastroenterology & Hepatology; orcid:0000-0003-0207-6706 (Chanchlani, Neil); Published online 16 April 2024; https://doi.org/10.1016/s2468-1253Test(24)00044-x; http://hdl.handle.net/10871/135783Test

الإتاحة: https://doi.org/10.1016/s2468-1253Test(24)00044-x
http://hdl.handle.net/10871/135783Test

المؤلفون: Sazonovs, A, Kennedy, NA, Moutsianas, L, Heap, GA, Rice, DL, Reppell, M, Bewshea, CM, Chanchlani, N, Walker, GJ, Perry, MH, McDonald, TJ, Lees, CW, Cummings, JRF, Parkes, M, Mansfield, JC, Irving, PM, Barrett, JC, McGovern, D, Goodhand, JR, Anderson, CA, Ahmad, T, Patel, V, Mazhar, Z, Saich, R, Colleypriest, B, Tham, TC, Iqbal, TH, Kaushik, V, Murugesan, S, Singh, S, Weaver, S, Preston, C, Butt, A, Smith, M, Basude, D, Beale, A, Langlands, S, Direkze, N, Torrente, F, De La Revella Negro, J, Ewen MacDonald, C, Evans, SM, Gunasekera, AVJ, Thakur, A, Elphick, D, Shenoy, A, Nwokolo, CU, Dhar, A, Cole, AT, Agrawal, A, Bridger, S, Doherty, J, Cooper, SC, De Silva, S, Mowat, C, Mayhead, P, Lees, C, Jones, G, Hart, JW, Gaya, DR, Russell, RK, Gervais, L, Dunckley, P, Mahmood, T, Banim, PJR, Sonwalkar, S, Ghosh, D, Phillips, RH, Azaz, A, Sebastian, S, Shenderey, R, Armstrong, L, Bell, C, Hariraj, R, Matthews, H, Jafferbhoy, H, Selinger, CP, Zamvar, V, De Caestecker, JS, Willmott, A, Miller, R, Sathish Babu, P, Tzivinikos, C, Bloom, SL, Chung-Faye, G, Croft, NM, Fell, JME, Harbord, M, Hart, A, Hope, B, Lindsay, JO, Mawdsley, JE, McNair, A, Monahan, KJ, Murray, CD, Orchard, T, Paul, T, Pollok, R, Shah, N, Bouri, S, Johnson, MW, Modi, A, Dawa Kabiru, K, Baburajan, BK, Bhaduri, B, Adebayo Fagbemi, A, Levison, S, Limdi, JK, Watts, G, Foley, S, Ramadas, A, MacFaul, G, Mansfield, J, Grellier, L, Morris, M-A, Tremelling, M, Hawkey, C, Kirkham, S, Charlton, CPJ, Rodrigues, A, Simmons, A, Lewis, SJ, Snook, J, Tighe, M, Goggin, PM, De Silva, AN, Lal, S, Smith, MS, Panter, S, Cummings, F, Dharmisari, S, Carter, M, Watts, D, Mahmood, Z, McLain, B, Sen, S, Pigott, AJ, Hobday, D, Wesley, E, Johnston, R, Edwards, C, Beckly, J, Vani, D, Ramakrishnan, S, Chaudhary, R, Trudgill, NJ, Cooney, R, Bell, A, Prasad, N, Gordon, JN, Brookes, MJ, Li, A, Gore, S

المصدر: 199 ; 189

مصطلحات موضوعية: Gastroenterology & Hepatology, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, 1109 Neurosciences

الوصف: Background & Aims Anti–tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to identify patients at increased risk for development of anti-drug antibodies would facilitate selection of therapy and use of preventative strategies. Methods We performed a genome-wide association study to identify variants associated with time to development of anti-drug antibodies in a discovery cohort of 1240 biologic-naïve patients with Crohn’s disease starting infliximab or adalimumab therapy. Immunogenicity was defined as an anti-drug antibody titer ≥10 AU/mL using a drug-tolerant enzyme-linked immunosorbent assay. Significant association signals were confirmed in a replication cohort of 178 patients with inflammatory bowel disease. Results The HLA-DQA1*05 allele, carried by approximately 40% of Europeans, significantly increased the rate of immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.60–2.25; P = 5.88 × 10–13). The highest rates of immunogenicity, 92% at 1 year, were observed in patients treated with infliximab monotherapy who carried HLA-DQA1*05; conversely the lowest rates of immunogenicity, 10% at 1 year, were observed in patients treated with adalimumab combination therapy who did not carry HLA-DQA1*05. We confirmed this finding in the replication cohort (HR, 2.00; 95% CI, 1.35–2.98; P = 6.60 × 10–4). This association was consistent for patients treated with adalimumab (HR, 1.89; 95% CI, 1.32–2.70) or infliximab (HR, 1.92; 95% CI, 1.57–2.33), and for patients treated with anti-TNF therapy alone (HR, 1.75; 95% CI, 1.37–2.22) or in combination with an immunomodulator (HR, 2.01; 95% CI, 1.57–2.58). Conclusions In an observational study, we found a genome-wide significant association between HLA-DQA1*05 and the development of antibodies against anti-TNF agents. A randomized controlled biomarker trial is required to determine whether ...

العلاقة: Gastroenterology; http://hdl.handle.net/10044/1/75682Test

الإتاحة: https://doi.org/10.1053/j.gastro.2019.09.041Test
http://hdl.handle.net/10044/1/75682Test

المؤلفون: Parmar, H, Jager, W, Bottomley, D, Phillips, RH, Lightman, SL

المصدر: European Journal of Cancer ; volume 29, page S134 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/0959-8049Test(93)91354-n
https://api.elsevier.com/content/article/PII:095980499391354N?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:095980499391354N?httpAccept=text/plainTest

المؤلفون: Parmar, H, Bottomley, D, Lloyd, G, Hanham, IW, Ghazali, S, Phillips, RH, Lightman, SL

المصدر: European Journal of Cancer ; volume 29, page S239 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/0959-8049Test(93)91965-n
https://api.elsevier.com/content/article/PII:095980499391965N?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:095980499391965N?httpAccept=text/plainTest

المؤلفون: Parmar, H, Bottomley, D, Hanham, IW, Phillips, RH, Lightman, SL

المصدر: European Journal of Cancer ; volume 29, page S102 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/0959-8049Test(93)91173-i
https://api.elsevier.com/content/article/PII:095980499391173I?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:095980499391173I?httpAccept=text/plainTest

المؤلفون: Parmar, H, Bottomley, D, Lloyd, G, Hanham, IW, Ghazali, S, Phillips, RH, Lightman, SL

المصدر: European Journal of Cancer ; volume 29, page S238 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/0959-8049Test(93)91959-o
https://api.elsevier.com/content/article/PII:095980499391959O?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:095980499391959O?httpAccept=text/plainTest

المؤلفون: Yost D (AUTHOR), Phillips RH (AUTHOR), Gonzales L (AUTHOR), Lick CJ (AUTHOR), Satterlee P (AUTHOR), Levy M (AUTHOR), Barger J (AUTHOR), Dodson P (AUTHOR), Poggi S (AUTHOR), Wojcik K (AUTHOR), Niskanen RA (AUTHOR), Chapman FW (AUTHOR)

المصدر: Resuscitation. Aug2012, Vol. 83 Issue 8, p961-965. 5p.

المؤلفون: Lightman Sl, Phillips Rh, L. Edwards, H. Parmar

المصدر: American journal of clinical oncology. 11

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Neoplasms, Hormone-Dependent, Urology, Antineoplastic Agents, Disease, Gonadotropin-Releasing Hormone, Random Allocation, Statistical significance, Internal medicine, Medicine, Humans, Testosterone, Prospective Studies, Triptorelin Pamoate, business.industry, Incidence (epidemiology), Significant difference, Remission Induction, Cancer, Prostatic Neoplasms, Testosterone (patch), Consumer Behavior, Luteinizing Hormone, medicine.disease, Follicle Stimulating Hormone, business, Orchiectomy

الوصف: One hundred thirteen patients were randomized for the study. There was no significant difference between the groups for response or survival. The incidence of side effects related to the reduction of testosterone was similar in both groups. Disease "flare" was seen in three patients treated with long-acting D-Trp-6 LH-RH. All symptoms resolved by the end of 8 weeks. There was less psychological morbidity in the D-Trp-6 LH-RH group but the difference did not reach statistical significance. Our results indicate that long-acting D-Trp-6 LH-RH offers a safe and effective alternative to surgical orchidectomy.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33eaa4fc47d95d4ab0bc5486eae4d7e0Test
https://pubmed.ncbi.nlm.nih.gov/2977271Test

المؤلفون: Musikanski, Laura, Phillips, Rhonda, Bradbury, James, de Graaf, John, Bliss, Clinton L.

مصطلحات موضوعية: community well-being, ecological sustainability, personal happiness, positive change theory, bic Book Industry Communication::R Earth sciences, geography, environment, planning::RN The environment::RNC Applied ecology, bic Book Industry Communication::R Earth sciences, geography, environment, planning::RN The environment::RND Environmental policy & protocols, bic Book Industry Communication::J Society & social sciences::JM Psychology, bic Book Industry Communication::V Health & personal development::VS Self-help & personal development::VSP Popular psychology::VSPM Assertiveness, motivation & self-esteem

الوصف: Happiness, Well-being and Sustainability: A Course in Systems Change is the first textbook bridging the gap between personal happiness and sustainable social change. The book provides a guide for students to increase their skills, literacy and knowledge about connections between a sense of well-being and systems change. Further, it can help students live a life that brings them happiness and contributes to the well-being of others and the sustainability of our planet. The book is presented in seven chapters covering the subjects of systems thinking, personal and societal values, measuring happiness, human needs, ecological sustainability and public policy. In addition, each section includes engaging exercises to empower students to develop their own ideas, prompts for group discussion, suggestions for additional research and an extensive list of resources and references. The book is written in the context of systems thinking with a style that is approachable and accessible. Happiness, Well-being and Sustainability provides essential reading for students in courses on happiness, social change and sustainability studies, and provides a comprehensive framework for instructors looking to initiate courses in this field. A website to support the professors teaching the book is available at: https://www.happycounts.org/coursebook.htmlTest The Open Access version of this book, available at http://www.taylorfrancis.comTest, has been made available under a Creative Commons Attribution-Non Commercial-No Derivatives (CC-BY-NC-ND) 4.0 license.

وصف الملف: application/pdf

الوصول الحر: https://library.oapen.org/handle/20.500.12657/75316Test

المؤلفون: Kelly RL, Armstrong FE, Horne CP, Hutchinson MS, Richards DR, Rittenberg A, Rosenfeld AH, Trippe TG, Yost GP, Addis L, Chadwick GB, Row GM, Fox GC, Stevens PR, Ward CEW, Phillips RH, Weilhammer P, Joos P, Groves TH, Arnison GTJ

العلاقة: Science Research Council (1966-1981); http://purl.org/net/epubs/work/21693Test

الإتاحة: http://purl.org/net/epubs/work/21693Test